Comparison of the Systemic Levels of Inflammatory Markers after Percutaneous Coronary Intervention with Bare Metal versus Sirolimus‐Eluting Stents

Rebeiz, Abdallah; Zoghbi, Elie; Harb, Rami; Youhanna, Sonia; Skouri, Hadi; Dimassi, Adel; Abou‐Nader, Gilbert; Nasrallah, Antoine; Sawaya, Jaber; Gharzuddine, Walid; Alam, Samir

doi:10.1111/j.1540-8183.2009.00429.x

Cited by 8 publications

(9 citation statements)

References 25 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have identified a significant increase in hsCRP and fibrinogen concentrations in blood of patients in the early period after stenting in comparison with the CA group. In accordance with published data [16,44,45], the levels of these acute-phase reactants did not depend on the type of implanted stent. Blood concentration of MCP-1 and other chemokines did not rise after the intervention, probably due to their predominantly paracrine action and more complex mechanisms of synthesis and elimination.…”

Section: Discussionsupporting

confidence: 76%

Synthetic peptide fragment (65–76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting

et al. 2011

View full text Add to dashboard Cite

Ingramon treatment was accompanied by less pronounced elevation of hsCRP and fibrinogen levels and decreased MCP-1 concentration in plasma in patients after coronary stenting. Ingramon had no effect on MCP-1 interaction with cell receptors or MCP-1 dimerization, but inhibited MCP-1 binding to heparin. The anti-inflammatory activity of the peptide may be mediated by an impaired chemokine interaction with glycosaminoglycans.

show abstract

Section: Discussionsupporting

confidence: 76%

Synthetic peptide fragment (65–76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Rebeiz et al found that systemic concentrations of CRP, IL-6, and MCP-1 increased substantially after PCI. 32 Sanchez-Margalet et al also found an increased serum CRP concentration following an increase in serum IL-6 levels by 12 to 36 hours, reaching a peak value by 24 hours after the procedure, 33 and the increase in serum IL-6 and CRP levels was more obvious in patients with a concomitant postprocedural troponin T elevation. 34 Although some other inflammatory factors, such as IL-1, TNF-α, 35 were also explored, CRP, IL-6, and MCP-1 were the most frequently studied inflammatory factors in the setting of PCI.…”

Section: Discussionmentioning

confidence: 92%

Effect of a Single High Loading Dose of Rosuvastatin on Percutaneous Coronary Intervention for Acute Coronary Syndromes

Wang

Dai

Xing

et al. 2013

J Cardiovasc Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…23 On the other hand, a DES group tended to show higher systemic levels of all proinflammatory markers compared with a BMS group. 24 Thus, the cause of this discrepancy is unclear and more precise data will be needed to resolve this issue.…”

Section: Discussionmentioning

confidence: 99%

Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation

et al. 2009

View full text Add to dashboard Cite

This study was performed to evaluate the safety and efficacy of additional antihypertensive therapy with angiotensin II type 1 receptor blocker (ARB; olmesartan or valsartan) after successful stent implantation in patients with coronary artery disease (CAD). Fifty patients with CAD after successful stent implantation were included in this study. They were divided into an ARB group, which initially received olmesartan (n¼20, 14±8 mg day À1 ) or valsartan (n¼20, 60±23 mg day À1 ) immediately after stent implantation, and a non-ARB group (n¼10) according to their blood pressure (BP). Follow-up coronary angiography, measurement of BP and blood sampling were performed before (at baseline) and 6-8 months after stent implantation (at follow-up). There were no significant differences in the baseline characteristics between the groups, except for BP. Although there were no changes in % diameter restenosis between the groups, the BP level in the ARB group at follow-up showed a significant reduction (125 ± 12/69 ± 9 mm Hg) and reached the target BP. There were no critical adverse effects in the ARB group throughout the study period. In addition, serum high-sensitive C-reactive protein (hs-CRP) and pentraxin 3 were significantly decreased in the ARB group but not in the non-ARB group. Although olmesartan and valsartan induced similar BP-lowering effects, olmesartan but not valsartan induced a significant decrease in hs-CRP, but did not increase serum uric acid. In conclusion, antihypertensive therapy with add-on low-dose ARB after stent implantation was safe and achieved the target BP. In particular, olmesartan had an anti-inflammatory effect.

show abstract

Comparison of the Systemic Levels of Inflammatory Markers after Percutaneous Coronary Intervention with Bare Metal versus Sirolimus‐Eluting Stents

Abstract: The use of SES did not inhibit the rise in systemic concentrations of CRP, IL-6, and MCP-1 at 24 hours or 30 days post-PCI, compared with BMS. Moreover, at 24 hours, there was a trend for higher systemic levels of all proinflammatory markers in the SES group compared with the BMS cohort.

Cited by 8 publications

References 25 publications

Synthetic peptide fragment (65–76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting

Synthetic peptide fragment (65–76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting

Effect of a Single High Loading Dose of Rosuvastatin on Percutaneous Coronary Intervention for Acute Coronary Syndromes

Safety and efficacy of antihypertensive therapy with add-on angiotensin II type 1 receptor blocker after successful coronary stent implantation

Contact Info

Product

Resources

About